genprowebdirectory
Facebook
Linkedin
RSS
Twitter
Youtube
GEN Edge
Featured News
Multimedia
News
Insights
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
Magazine
Browse Issues
Subscribe
Multimedia
Summits
Webinars
GEN Live
Learning Labs
Podcasts
Resources
A-Lists
eBooks/Perspectives
Tutorials
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Search
Facebook
Linkedin
RSS
Twitter
Youtube
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Privacy Policy
Password recovery
Recover your password
your email
A password will be e-mailed to you.
GEN – Genetic Engineering and Biotechnology News
GEN Edge
Featured News
Multimedia
News
Insights
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
Magazine
Browse Issues
Subscribe
Multimedia
Summits
Webinars
GEN Live
Learning Labs
Podcasts
Resources
A-Lists
eBooks/Perspectives
Tutorials
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Home
2012
BioWa
Cancer
FivePrime Licenses BioWa, Lonza’s Cell Line for Anticancer Antibody Pipeline
Cancer
ArGEN-X Licenses BioWa’s Potelligent Platform to Generate More Potent Antibodies
Drug Discovery
ImmunoCellular Therapeutics to Leverage BioWa’s Antibody Platform
Cancer
Oxford BioTherapeutics Licenses BioWa Platform to Develop Antibody Therapeutics
Bioprocessing
Kalobios Chooses BioWa and Lonza’s Potelligent CHOK1SV Cell Line
Cancer
Agensys Taps BioWa Technology for Cancer Antibody Discovery
News
NKTT Gains Access to BioWa’s Platform for Use in Antibody R&D
News
KaloBios Licenses Biowa’s Antibody-Enhancing Platform
News
BioWa and Lonza Will Pool Tools to Develop Enhanced Antibody Platform
News
GSK Licenses BioWa Tool for Antibody R&D
1
2
Page 1 of 2
Scroll Up
Scroll Up
